Tempus Acquires Deep 6 AI

Tempus AI to Acquire Personalis for $1.5 Billion to Expand MRD Precision Oncology Monitoring

July 21, 2026

Healthcare Services

Tempus AI has entered into a definitive agreement to acquire Personalis in a transaction with an enterprise value of approximately $1.5 billion (net of Tempus’ existing stake). Personalis shareholders will receive $16.25 per share, with consideration primarily structured as Tempus stock and Tempus having the option to pay up to 50% in cash. The deal is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory clearances, and customary closing conditions.

Rapid Care Acquires DeepDoc to Expand AI-Powered Medical Record Intelligence

January 23, 2026

AI & Machine Learning

Rapid Care has acquired DeepDoc, a generative AI platform that analyzes and summarizes unstructured medical records to create concise, searchable clinical intelligence. Rapid Care said the deal deepens its AI roadmap and strengthens its ability to streamline “patient-to-payment” workflows across insurance, medicolegal, independent medical exams, and utilization review.

Hippocratic AI Acquires Grove AI

January 12, 2026

AI & Machine Learning

Hippocratic AI has acquired Grove AI to accelerate its Life Sciences Division, integrating Grove AI's agentic AI platform and team to expand clinical engagement and trial operations capabilities. The move complements Hippocratic AI's Polaris safety architecture and follows its recent $126M Series C, while the company also launched a Life Sciences Executive Advisory Council and a strategic collaboration with BCG.

Tempus AI Acquires Paige for $81.25 Million

August 25, 2025

Healthcare Services

Tempus AI, Inc. (NASDAQ: TEM) is acquiring digital pathology company Paige for $81.25 million, primarily paid in Tempus common stock, and will assume Paige's remaining Microsoft Azure commitments. The deal expands Tempus's pathology dataset, technical team, and generative AI capabilities to accelerate development of large oncology foundation models and strengthen its precision medicine platform.

Tempus Acquires Highline Sciences

February 8, 2022

Healthcare Services

Tempus, the Chicago-based AI-driven precision medicine company, has acquired Highline Sciences, a San Francisco-based full-service clinical CRO focused on oncology. The acquisition will allow Tempus to vertically integrate additional clinical trial services and expand its capabilities to support and grow clinical research offerings for oncology therapeutics.

RadNet Acquires DeepHealth to Expand AI Capabilities

March 11, 2020

AI & Machine Learning

RadNet, Inc. has executed a definitive agreement to acquire DeepHealth, Inc., a Cambridge-based radiology AI and machine learning company focused on mammography and 3D breast imaging. The deal is structured as an initial share payment with up to additional milestone-based stock payments and aims to integrate DeepHealth's team and technology into RadNet's AI strategy to improve imaging interpretation and workflow efficiency.